Coenzyme Q10 in Huntington’s Disease

The HSG is funded to conduct a definitive clinical trial of high dose coenzyme Q10 (CoQ) in Huntington’s disease (HD). The initial steps in planning for the 2CARE study (Coenzyme Q10 in Huntington’s Disease), in which several hundred people with HD will be enrolled, included carrying out some smaller, shorter-term studies to determine what the appropriate dosage of CoQ should be in 2CARE.

These studies also assessed whether or not the use of CoQ at the selected dosage, which will be much higher than what people typically take when buying CoQ on their own, is safe and does not pose any unnecessary health risks in the short-term.

For more information please contact Denyse Turpin, RN, MPH at 617-638-7736.

August 7, 2015
Primary teaching affiliate
of BU School of Medicine